06/15/2017

NCCN has published updates to the NCCN Guidelines®, the NCCN Compendium®), the NCCN Radiation Therapy Compendium™ and the NCCN Imaging AUC™ for Neuroendocrine Tumors

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Neuroendocrine Tumors.  These NCCN Guidelines^® are currently available as Version 3.2017. 

• Neuroendocrine Tumors of the Gastrointestinal Tract, Lung and Thymus- Carcinoid Syndrome (NET-10)
  • A new page has been added to expand on the recommendations for carcinoid syndrome.
  • Telotristat has been added as an option for consideration, in combination with octreotide or lanreotide, for persistent diarrhea from poorly controlled carcinoid syndrome. The following footnote has been included: "Telotristat is not indicated for flushing due to poorly controlled carcinoid syndrome."

• Reference: Kulke MH, Hörsch D, Caplin ME, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017; 35(1):14-23.
  • The principles of systemic therapy have been updated to include the options for carcinoid syndrome. (NE-D, 1 of 3)

• The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 2.2017) to the NCCN Guidelines for Neuroendocrine Tumors, published on March 29, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf